Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TS-143 in Healthy Males
NCT03595202Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Apr 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TS-143 in anemia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Incidence of subjects with adverse events at 18 days, Plasma concentrations of unchanged form at 13 days and 6 more. Started Apr 2017; status: completed.
02
Drugs
TS-143
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03595202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03595202.